IRD

Opus Genetics, Inc. (IRD) - 10-K Summary

Business Context and Reporting Period

This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for ophthalmic disorders. In October 2024, the Company completed the acquisition of "Private Opus," significantly expanding its gene therapy pipeline. The Company operates as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Revenue is derived primarily from the Viatris License Agreement (reimbursement of R&D costs and milestone payments). The Company has no product sales revenue from its own commercialization efforts as of the reporting date.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by $3.2 million (29%) to $14.2 million, driven by continued R&D reimbursement and milestone recognition under the Viatris License Agreement.
• Expense Reduction: Total operating expenses decreased by $20.3 million to $52.8 million. This reduction was primarily due to the absence of $28.0 million in non-cash Acquired In-Process Research and Development (IPR&D) expenses recorded in 2024 related to the Opus Acquisition.
• Net Loss Improvement: Net loss narrowed by $7.9 million to $49.6 million, reflecting the lower operating expenses despite a $11.5 million expense related to the fair value change in warrant liabilities.
• Capital Structure: The Company raised approximately $50.0 million in net proceeds from financing activities in 2025, including a Registered Direct Offering in November 2025 and private placements in March and August 2025. This resulted in a net increase in cash of $14.8 million.
• Warrant Liability: A new warrant liability of $26.0 million was recorded in 2025 due to the issuance of warrants in March 2025 that were classified as liabilities under accounting standards.

Guidance, Outlook, and Risks

Outlook and Milestones:

• OPGx-LCA5: Positive Phase 1/2 data reported in September 2025. The Company plans to submit an application under the FDA's Rare Disease Evidence Principles (RDEP) in Q1 2026. Dosing in the Phase 3 portion is anticipated in H2 2026.
• OPGx-BEST1: First participant dosed in November 2025. Three-month results from Cohort 1 are expected mid-2026.
• Phentolamine (PS): Viatris filed an sNDA for presbyopia in December 2025; the FDA set a PDUFA date of October 17, 2026. The LYNX-3 trial for low-light vision disturbances is ongoing, with topline data expected in H1 2026.
• APX3330: The Company is seeking a strategic partner to advance this diabetic retinopathy program and is redirecting resources to gene therapies.

Risks and Contingencies:

• Liquidity: While the Company believes cash on hand ($45.1 million) plus subsequent financing ($25.0 million in Feb 2026) is sufficient for 12 months, it expects to incur losses for the foreseeable future and will require additional capital.
• Patent Litigation: The Company is engaged in patent infringement litigation against Sandoz regarding RYZUMVI, with a trial scheduled for January 2027.
• Regulatory Uncertainty: Success depends on FDA approvals for gene therapies and PS indications. Delays or failures in clinical trials could materially harm the business.
• Stock Price Volatility: The stock price has traded below the $1.00 Nasdaq minimum bid price requirement, posing a risk of delisting if compliance is not regained.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $45.1 million cash balance (plus $25.0 million subsequent private placement) against the projected burn rate for advancing Phase 3 trials for LCA5 and BEST1.
• Warrant Liability Impact: Assess the volatility risk associated with the $26.0 million warrant liability, which fluctuates with the Company's stock price and contributed significantly to the 2025 net loss.
• Viatris Partnership: Confirm the status of the sNDA for PS (presbyopia) and the timeline for the PDUFA decision (Oct 2026), as this is a key near-term revenue driver.
• Authorized Shares: Note the Company's limited authorized share count (125 million) and the pending request to increase this at the 2026 Annual Meeting to facilitate future fundraising.
• Patent Litigation: Monitor the progress of the Sandoz litigation, as a loss could impact the exclusivity and future royalty potential of RYZUMVI.